ArticleMolecular therapy. Nucleic acids2019
Neutral Lipopolyplexes for In Vivo Delivery of Conventional and Replicative RNA Vaccine.
Article in Molecular therapy. Nucleic acids, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 53 citations in OpenAlex.
- Spatiotemporal control of STING activation and saRNA delivery decouples humoral and cellular immunity.bioRxiv : the preprint server for biology · 2026Article
- Hyperbranched Polylysine-Based Lipopolyplexes Enable Efficient mRNA Delivery With Long-Term Storage Stability.Advanced healthcare materials · 2026Article
- The Impact of Using Different Cationic Polymers on the Formation of Efficient Lipopolyplexes for pDNA Delivery.International journal of nanomedicine · 2025Article
- Advances in drug delivery systems utilizing blood cells and their membrane-derived microvesicles.Drug delivery · 2024Review
- Designing Polyelectrolyte Microneedles Based on Borylated Poly(β-aminoester) Polymers To Enhance Transdermal pH-Controlled Delivery of Nucleic Acids.ACS applied polymer materials · 2024Article
- Oligonucleotide therapies for nonalcoholic steatohepatitis.Molecular therapy. Nucleic acids · 2024Review
- Transitional Insight into the RNA-Based Oligonucleotides in Cancer Treatment.Applied biochemistry and biotechnology · 2024Review
- Review
- Nanomaterials for mRNA-based therapeutics: Challenges and opportunities.Bioengineering & translational medicine · 2023Review
- mRNA-From COVID-19 Treatment to Cancer Immunotherapy.Biomedicines · 2023Review
- Scope and challenges of nanoparticle-based mRNA delivery in cancer treatment.Archives of pharmacal research · 2022Review
- Emerging trends of research on mRNA vaccines: A co-citation analysis.Human vaccines & immunotherapeutics · 2022Article
- Enhancing the Effect of Nucleic Acid Vaccines in the Treatment of HPV-Related Cancers: An Overview of Delivery Systems.Pathogens (Basel, Switzerland) · 2022Review
- Self-Amplifying RNA Approach for Protein Replacement Therapy.International journal of molecular sciences · 2022Review
- In Cellulo and In Vivo Comparison of Cholesterol, Beta-Sitosterol and Dioleylphosphatidylethanolamine for Lipid Nanoparticle Formulation of mRNA.Nanomaterials (Basel, Switzerland) · 2022Article
- In vivo fate and intracellular trafficking of vaccine delivery systems.Advanced drug delivery reviews · 2022Review
- Nucleic acid and oligonucleotide delivery for activating innate immunity in cancer immunotherapy.Journal of controlled release : official journal of the Controlled Release Society · 2022Review
- Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action.Current topics in microbiology and immunology · 2022Article
- Polyethyleneimine-Based Lipopolyplexes as Carriers in Anticancer Gene Therapies.Materials (Basel, Switzerland) · 2021Review
- New Applications of Lipid and Polymer-Based Nanoparticles for Nucleic Acids Delivery.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nucleic acid vaccination relies on injecting DNA or RNA coding antigen(s) to induce a protective immune response. RNA vaccination is being increasingly used in preclinical and clinical studies. However, few delivery systems have been reported for in vivo delivery of RNA of different sizes. Using a tripartite formulation with RNA, cationic polymer, and anionic liposomes, we were able to encapsulate RNA into neutral lipopolyplexes (LPPs). LPPs were stable in vitro and successfully delivered conventional RNA and replicative RNA to dendritic cells in cellulo. Their injection led to reporter gene expression in mice. Finally, administration of LPP-Replicon RNA (RepRNA) led to an adaptive immune response against the antigen coded by the RepRNA. Accordingly, LPPs may represent a universal formulation for RNA delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.